Adocia is a privately held French biotechnology company specialized in protein delivery. Adocia has created and developed a unique technology, BioChaperone^TM, to provide a spatio-temporal control of protein activity.

Adocia's mission is to offer innovative treatments for tissue regeneration based on growth factors. The first two products, BioChaperone PDGF-BB for wound healing and BioChaperone BMP for bone repair, have generated positive results in animal testing and will shortly enter clinical trials.

Based on these results with growth factors, Adocia aims at expanding BioChaperone^TM as a Molecular Delivery Platform for proteins, such as monoclonal antibodies, hormones…

Adocia intends to license BioChaperone^TM to Biotechnology, Pharmaceutical and Medical Device Companies.